These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 3320851)

  • 21. [Drug therapy of ovarian carcinoma].
    Dittrich C
    Wien Med Wochenschr; 1996; 146(1-2):23-34. PubMed ID: 8835492
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Combined chemo- and hormone-therapy in advanced ovarian carcinoma--theoretical, experimental foundations and clinical results].
    Sevelda P
    Wien Klin Wochenschr Suppl; 1990; 183():3-29. PubMed ID: 2145702
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.
    Pasmantier MW; Coleman M; Silver RT; Ballard WP
    Cancer Treat Rep; 1985 Jun; 69(6):689-93. PubMed ID: 3926310
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer.
    Rose PG
    Oncologist; 2005 Mar; 10(3):205-14. PubMed ID: 15793224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Efficacy of mono- and polychemotherapy in patients with advanced ovarian cancer].
    Khasanova DT; Kotova DG
    Vopr Onkol; 1984; 30(3):67-71. PubMed ID: 6369776
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical efficacy analysis of chemotherapy to lymph node metastasis in epithelial ovarian cancer].
    Wu LY; Zhang R; Huang MN; Li N; Wang GX; Liu LY
    Ai Zheng; 2003 Apr; 22(4):424-7. PubMed ID: 12704005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Therapeutic effectiveness of various combination chemotherapy protocols in advanced epithelial ovarian cancer].
    Petru E; Schmähl D
    Geburtshilfe Frauenheilkd; 1986 Nov; 46(11):783-9. PubMed ID: 3803871
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Docetaxel: new preparation. No first-line use in metastatic breast cancer.
    Prescrire Int; 2001 Dec; 10(56):178-9. PubMed ID: 11824441
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
    Thigpen T; Vance R; Puneky L; Khansur T
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pegylated liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked, advanced-stage epithelial ovarian cancer patients.
    Rocconi RP; Straughn JM; Leath CA; Kilgore LC; Huh WK; Barnes MN; Partridge EE; Alvarez RD
    Oncologist; 2006 Apr; 11(4):336-41. PubMed ID: 16614229
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemotherapy for stage III-IV epithelial ovarian cancer with cis-dichlorodiammineplatinum(II), adriamycin, and cyclophosphamide: a preliminary report.
    Ehrlich CE; Einhorn L; Williams SD; Morgan J
    Cancer Treat Rep; 1979 Feb; 63(2):281-8. PubMed ID: 376134
    [No Abstract]   [Full Text] [Related]  

  • 33. Cisplatin (P) versus cyclophosphamide, adriamycin and cisplatin (CAP) for stage III-IV epithelial ovarian carcinoma: a prospective randomized trial.
    Tomirotti M; Perrone S; Giè P; Canaletti R; Carpi A; Biasoli R; Lombardi F; Giovanninetti A; Mensi F; Villa S
    Tumori; 1988 Oct; 74(5):573-7. PubMed ID: 3217992
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ovarian cancer chemotherapy: carboplatin as standard.
    Tattersall MN
    Lancet; 2002 Aug; 360(9332):500-1. PubMed ID: 12241648
    [No Abstract]   [Full Text] [Related]  

  • 35. Differing response rates and survival between squamous and non-squamous non-small cell lung cancer. Comparison of CAP versus MAP.
    Eagan RT; Frytak S; Creagan ET; Richardson RL; Coles DT; Jett JR
    Am J Clin Oncol; 1986 Jun; 9(3):249-54. PubMed ID: 3755281
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cyclophosphamide, adriamycin and platinum (CAP) combination chemotherapy, a new effective approach in the treatment of disseminated breast cancer. Preliminary report.
    Kolarić K; Vukas D; Roth A; Potrebica V; Cervek J; Cerar O
    Tumori; 1985 Apr; 71(2):159-65. PubMed ID: 3890307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Complete remission at laparotomy: still a gold standard in ovarian cancer?
    Neijt JP; ten Bokkel Huinink WW; Van der Burg ME; van Oosterom AT
    Lancet; 1986 May; 1(8488):1028. PubMed ID: 2871299
    [No Abstract]   [Full Text] [Related]  

  • 38. Adriamycin, BCNU, and cyclophosphamide in drug-resistant adenocarcinoma of the ovary.
    Presant CA; Bartolucci A
    Med Pediatr Oncol; 1983; 11(3):151-3. PubMed ID: 6682929
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Retrospective evaluation of the results of two-drug chemotherapy in patients with advanced ovarian cancer].
    Kwaśniewska-Rokicińska C
    Ginekol Pol; 1987 Dec; 58(12):827-30. PubMed ID: 3454340
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical aspects of ovarian tumors of low malignant potential.
    Dgani R; Blickstein I; Shoham Z; Czernobilsky B; Ben-Hur H; Shani A; Katz Z; Borenstein R
    Eur J Obstet Gynecol Reprod Biol; 1990; 35(2-3):251-8. PubMed ID: 2159428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.